Uncovering the pharmacological response of novel sesquiterpene derivatives that differentially alter gene expression and modulate the cell cycle in cancer cells

Akrivou,Melpomeni  G.; Demertzidou,Vera   P.; Theodoroula,Nikoleta  F.; Chatzopoulou,Fani  M.; Kyritsis,Konstantinos  A.; Grigoriadis,Nikolaos; Zografos,Alexandros  L.; Vizirianakis,Ioannis   S.

doi:10.3892/ijo.2018.4550

Uncovering the pharmacological response of novel sesquiterpene derivatives that differentially alter gene expression and modulate the cell cycle in cancer cells

Authors:
- Melpomeni G. Akrivou
- Vera P. Demertzidou
- Nikoleta F. Theodoroula
- Fani M. Chatzopoulou
- Konstantinos A. Kyritsis
- Nikolaos Grigoriadis
- Alexandros L. Zografos
- Ioannis S. Vizirianakis
View Affiliations

Affiliations: Department of Pharmacology, School of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece, Department of Chemistry, Laboratory of Organic Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece, Labnet Laboratories, 54638 Thessaloniki, Greece, Biogenea Pharmaceuticals Ltd., 54627 Thessaloniki, Greece
Published online on: September 3, 2018 https://doi.org/10.3892/ijo.2018.4550
Pages: 2167-2179

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to assess the pharmacological anticancer profile of three natural and five synthetic sesquiterpenes developed by total chemical synthesis. To this end, their properties at the cellular and molecular level were evaluated in a panel of normal and cancer cell lines. The results obtained by performing cytotoxicity assays and gene expression analysis by reverse transcription-quantitative polymerase chain reaction showed that: i) Among the sesquiterpene derivatives analyzed, VDS58 exhibited a notable anticancer profile within attached (U-87 MG and MCF-7) and suspension (K562 and MEL-745) cancer cell cultures; however, U-87 MG cells were able to recover their proliferation capacity rapidly after 48 h of exposure; ii) gene expression profiling of U-87 MG cells, in contrast to K562 cells, showed a transient induction of cyclin-dependent kinase inhibitor 1A (CDKN1) expression; iii) the expression levels of transforming growth factor β1 (TGFB1) increased after 12 h of exposure of U-87 MG cells to VDS58 and were maintained at this level throughout the treatment period; iv) in K562 cells exposed to VDS58, TGFB1 expression levels were upregulated for 48 h and decrease afterwards; and v) the re-addition of VDS58 in U-87 MG cultures pretreated with VDS58 resulted in a notable increase in the expression of caspases (CASP3 and CASP9), BCL2‑associated agonist of cell death (BAD), cyclin D1, CDK6, CDKN1, MYC proto-oncogene bHLH transcription factor (MYC), TGFB1 and tumor suppressor protein p53. This upregulation persisted only for 24 h for the majority of genes, as afterwards, only the expression of TGFB1 and MYC was maintained at high levels. Through bioinformatic pathway analysis of RNA-Seq data of parental U-87 MG and K562 cells, substantial variation was reported in the expression profiles of the genes involved in the regulation of the cell cycle. This was associated with the differential pharmacological profiles observed in the same cells exposed to VDS58. Overall, the data presented in this study provide novel insights into the molecular mechanisms of action of sesquiterpene derivatives by dysregulating the expression levels of genes associated with the cell cycle of cancer cells.

View Figures

View References

1	Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J and Sawyers CL: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2:117–125. 2002. View Article : Google Scholar : PubMed/NCBI
2	Newman DJ and Cragg GM: Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod. 75:311–335. 2012. View Article : Google Scholar : PubMed/NCBI
3	Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT and Sim GA: Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc. 88:3888–3890. 1966. View Article : Google Scholar
4	Cragg GM and Newman DJ: Nature: A vital source of leads for anticancer drug development. Phytochem Rev. 8:313–331. 2009. View Article : Google Scholar
5	Song Y, Sun H, Zhang A, Yan G, Han Y and Wang X: Plant-derived natural products as leads to anti-cancer drugs. J Med Plant Herb Ther Res. pp. 6–15. 2014
6	Vizirianakis IS, Chatzopoulou M, Bonovolias ID, Nicolaou I, Demopoulos VJ and Tsiftsoglou AS: Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: Clinical candidates and perspectives. J Med Chem. 53:6779–6810. 2010. View Article : Google Scholar : PubMed/NCBI
7	Tao W, Li B, Gao S, Bai Y, Shar PA, Zhang W, Guo Z, Sun K, Fu Y, Huang C, et al: CancerHSP: Anticancer herbs database of systems pharmacology. Sci Rep. 5:114812015. View Article : Google Scholar : PubMed/NCBI
8	Kreuger MRO, Grootjans S, Biavatti MW, Vandenabeele P and D’Herde K: Sesquiterpene lactones as drugs with multiple targets in cancer treatment: Focus on parthenolide. Anticancer Drugs. 23:883–896. 2012.PubMed/NCBI
9	Ren Y, Yu J and Kinghorn AD: Development of anticancer agents from plant-derived sesquiterpene lactones. Curr Med Chem. 23:2397–2420. 2016. View Article : Google Scholar : PubMed/NCBI
10	Bosco A and Golsteyn RM: Emerging anti-mitotic activities and other bioactivities of sesquiterpene compounds upon human cells. Molecules. 22:4592017. View Article : Google Scholar
11	Zhou J and Zhang Y: Cancer stem cells: Models, mechanisms and implications for improved treatment. Cell Cycle. 7:1360–1370. 2008. View Article : Google Scholar : PubMed/NCBI
12	Jordan CT: Searching for leukemia stem cells - not yet the end of the road? Cancer Cell. 10:253–254. 2006. View Article : Google Scholar : PubMed/NCBI
13	Kawasaki BT, Hurt EM, Kalathur M, Duhagon MA, Milner JA, Kim YS and Farrar WL: Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells: An integrated molecular profiling approach. Prostate. 69:827–837. 2009. View Article : Google Scholar : PubMed/NCBI
14	Efferth T, Sauerbrey A, Olbrich A, Gebhart E, Rauch P, Weber HO, Hengstler JG, Halatsch ME, Volm M, Tew KD, et al: Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol. 64:382–394. 2003. View Article : Google Scholar : PubMed/NCBI
15	Ji Y, Zhang YC, Pei LB, Shi LL, Yan JL and Ma XH: Anti-tumor effects of dihydroartemisinin on human osteosarcoma. Mol Cell Biochem. 351:99–108. 2011. View Article : Google Scholar : PubMed/NCBI
16	Gravett AM, Liu WM, Krishna S, Chan WC, Haynes RK, Wilson NL and Dalgleish AG: In vitro study of the anti-cancer effects of artemisone alone or in combination with other chemotherapeutic agents. Cancer Chemother Pharmacol. 67:569–577. 2011. View Article : Google Scholar
17	Zhang CZ, Zhang H, Yun J, Chen GG and Lai PB: Dihydroartemisinin exhibits antitumor activity toward hepatocellular carcinoma in vitro and in vivo. Biochem Pharmacol. 83:1278–1289. 2012. View Article : Google Scholar : PubMed/NCBI
18	Zografos AL and Anagnostaki EE: Sesquiterpenes. From Biosynthesis to Total Synthesis: Strategies and Tactics for Natural Products. John Wiley & Sons, Inc; pp. 254–278. 2016
19	Anagnostaki EE and Zografos AL: ‘Common synthetic scaffolds’ in the synthesis of structurally diverse natural products. Chem Soc Rev. 41:5613–5625. 2012. View Article : Google Scholar : PubMed/NCBI
20	Anagnostaki EE and Zografos AL: Non-natural elemane as the ‘stepping stone’ for the synthesis of germacrane and guaiane sesquiterpenes. Org Lett. 15:152–155. 2013. View Article : Google Scholar
21	Anagnostaki EE, Demertzidou VP and Zografos AL: Divergent pathways to furosesquiterpenes: First total syntheses of (+)-zedoarol and (Rac)-gweicurculactone. Chem Commun (Camb). 51:2364–2367. 2015. View Article : Google Scholar
22	Tseligka ED, Rova A, Amanatiadou EP, Calabrese G, Tsibouklis J, Fatouros DG and Vizirianakis IS: Pharmacological development of target-specific delocalized lipophilic cation-functionalized carboranes for cancer therapy. Pharm Res. 33:1945–1958. 2016. View Article : Google Scholar : PubMed/NCBI
23	Vizirianakis IS and Tsiftsoglou AS: Blockade of murine erythroleukemia cell differentiation by hypomethylating agents causes accumulation of discrete small poly(A)-RNAs hybridized to 3′-end flanking sequences of beta(major) globin gene. Biochim Biophys Acta. 1743:101–114. 2005. View Article : Google Scholar : PubMed/NCBI
24	Friend C, Scher W, Holland JG and Sato T: Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: Stimulation of erythroid differentiation by dimethyl sulfoxide. Proc Natl Acad Sci USA. 68:378–382. 1971. View Article : Google Scholar : PubMed/NCBI
25	Vizirianakis IS, Wong W and Tsiftsoglou AS: Analysis of the inhibition of commitment of murine erythroleukemia (MEL) cells to terminal maturation by N6-methyladenosine. Biochem Pharmacol. 44:927–936. 1992. View Article : Google Scholar : PubMed/NCBI
26	Allen M, Bjerke M, Edlund H, Nelander S and Westermark B: Origin of the U87MG glioma cell line: Good news and bad news. Sci Transl Med. 8:pp. 354re32016, View Article : Google Scholar : PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−ΔΔC(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
28	Dunham I, Kundaje A, Aldred SF, Collins PJ, Davis CA, Doyle F, Epstein CB, Frietze S, Harrow J, Kaul R, et al ENCODE Project Consortium: An integrated encyclopedia of DNA elements in the human genome. Nature. 489:57–74. 2012. View Article : Google Scholar
29	Luo W and Brouwer C: Pathview: An R/Bioconductor package for pathway-based data integration and visualization. Bioinformatics. 29:1830–1831. 2013. View Article : Google Scholar : PubMed/NCBI
30	Kanehisa M and Goto S: KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28:27–30. 2000. View Article : Google Scholar
31	Kanehisa M, Sato Y, Kawashima M, Furumichi M and Tanabe M: KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 44:D457–D462. 2016. View Article : Google Scholar :
32	Kanehisa M, Furumichi M, Tanabe M, Sato Y and Morishima K: KEGG: New perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 45:D353–D361. 2017. View Article : Google Scholar :
33	Gottesman MM, Lavi O, Hall MD and Gillet JP: Toward a better understanding of the complexity of cancer drug resistance. Annu Rev Pharmacol Toxicol. 56:85–102. 2016. View Article : Google Scholar
34	Hartwell JL and Abbott BJ: Antineoplastic principles in plants: Recent developments in the field. Adv Pharmacol Chemother. 7:117–209. 1969. View Article : Google Scholar : PubMed/NCBI
35	Ghantous A, Gali-Muhtasib H, Vuorela H, Saliba NA and Darwiche N: What made sesquiterpene lactones reach cancer clinical trials? Drug Discov Today. 15:668–678. 2010. View Article : Google Scholar : PubMed/NCBI
36	Merfort I: Perspectives on sesquiterpene lactones in inflammation and cancer. Curr Drug Targets. 12:1560–1573. 2011. View Article : Google Scholar : PubMed/NCBI
37	Lytton J, Westlin M and Hanley MR: Thapsigargin inhibits the sarcoplasmic or endoplasmic reticulum Ca-ATPase family of calcium pumps. J Biol Chem. 266:17067–17071. 1991.PubMed/NCBI
38	Hehner SP, Heinrich M, Bork PM, Vogt M, Ratter F, Lehmann V, Schulze-Osthoff K, Dröge W and Schmitz ML: Sesquiterpene lactones specifically inhibit activation of NF-kappa B by preventing the degradation of I kappa B-alpha and I kappa B-beta. J Biol Chem. 273:1288–1297. 1998. View Article : Google Scholar : PubMed/NCBI
39	Ghantous A, Sinjab A, Herceg Z and Darwiche N: Parthenolide: From plant shoots to cancer roots. Drug Discov Today. 18:894–905. 2013. View Article : Google Scholar : PubMed/NCBI
40	Demertzidou VP and Zografos AL: Platinum-catalyzed cycloisomerizations of a common enyne: A divergent entry to cyclopropane sesquiterpenoids. Formal synthesis of sarcandral-actone A. Org Biomol Chem. 14:6942–6946. 2016. View Article : Google Scholar : PubMed/NCBI
41	Foo K, Usui I, Götz DCG, Werner EW, Holte D and Baran PS: Scalable, enantioselective synthesis of germacrenes and related sesquiterpenes inspired by terpene cyclase phase logic. Angew Chem Int Ed Engl. 51:11491–11495. 2012. View Article : Google Scholar : PubMed/NCBI
42	Hu X, Xu S and Maimone TJ: A double allylation strategy for gram-scale guaianolide production: Total synthesis of (+)-mika-nokryptin. Angew Chem Int Ed Engl. 56:1624–1628. 2017. View Article : Google Scholar : PubMed/NCBI
43	Warfel NA and El-Deiry WS: p21WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol. 25:52–58. 2013. View Article : Google Scholar
44	Muñoz-Espín D and Serrano M: Cellular senescence: From physiology to pathology. Nat Rev Mol Cell Biol. 15:482–496. 2014. View Article : Google Scholar : PubMed/NCBI
45	Abbas T and Dutta A: p21 in cancer: Intricate networks and multiple activities. Nat Rev Cancer. 9:400–414. 2009. View Article : Google Scholar : PubMed/NCBI
46	Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R and Jacks T: Restoration of p53 function leads to tumour regression in vivo. Nature. 445:661–665. 2007. View Article : Google Scholar : PubMed/NCBI
47	Wu CH, van Riggelen J, Yetil A, Fan AC, Bachireddy P and Felsher DW: Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci USA. 104:13028–13033. 2007. View Article : Google Scholar : PubMed/NCBI
48	Bretones G, Delgado MD and León J: Myc and cell cycle control. Biochim Biophys Acta. 1849:506–516. 2015. View Article : Google Scholar